## **Cell Culture Engineering XVIII**

Cancun, Mexico 23-28 April 2023

ISBN: 978-1-7138-9205-2

## Printed from e-media with permission by:

Curran Associates, Inc. 57 Morehouse Lane Red Hook, NY 12571



Some format issues inherent in the e-media version may also appear in this print version.

Copyright© (2023) by Engineering Conferences International All rights reserved.

Printed with permission by Curran Associates, Inc. (2024)

For permission requests, please contact Engineering Conferences International at the address below.

Engineering Conferences International 32 Broadway, Suite 314 New York, NY 10004 USA

Phone: (212) 514-6760 Fax: (212) 514-6030

info@engconfintl.org

## Additional copies of this publication are available from:

Curran Associates, Inc. 57 Morehouse Lane Red Hook, NY 12571 USA Phone: 845-758-0400

Fax: 845-758-2633

Email: curran@proceedings.com Web: www.proceedings.com

## TABLE OF CONTENTS

| <u>KEYNOTES</u>  |
|--|
| Cell Culture Engineering - and What This Means for the Future of Medicine  |
| Human Gene Therapy - Principles, History, State of the Art, Challenges and Approaches for Mitigation                                   |
| AWARD LECTURES   |
| Cell Culture and Social Engineering  |
| Accelerated Process Development and Commercialization - Bringing Life-saving Drugs to Market   |
| SESSION 1: MULTISPECIFIC MODALITIES COMMERCIALIZATION SUCCESSES & FUTURE TRENDS  |
| Continuous Improvement in Bispecifics Manufacturing: Advantages and Disadvantages of 2-Cell Vs. 1-Cell Culture Process                 |
| Cellular Demands of Secreted Protein Products – Systems and Synthetic Biology Improve Quality and Titer                                |
| Johan Rockberg   |
| Insights into Bispecific Antibody Development, Characterization, Andmanufacture  |
| Building One Block at a Time Toward Complex Biologics Using Cell-Free Protein Synthesis Process  |
| Marcella Yu  |
| Transforming Molecule Selection and Process Development Through Attribute Focus and the Deployment of High-Performance Computing Tools |
| Regeneron Bispecific Molecule Structure Begets Platform Production Process Compatibility   |
| Challenges and Successes in Developing and Manufacturing Multiple Formats of Bispecific Antibodies                                     |

| SESSION 2: CELL LINE DEVELOPMENT CURRENT STATE AND FUTURE DIRECTION   | S        |
|---|----------|
| Cell Line Technologies for Speed-To-clinic and Commercial Production of Biologics   | 3        |
| Chromosomal Instability Drives Convergent and Divergent Evolution Toward Advantageous Inherited Traits in Mammalian CHO Bioproduction Lineages  | 4        |
| What's in a Phenotype?  | 5        |
| Newly-Established Chinese Hamster-derived Cell Line for Protein Production  | 6        |
| Engineering of Chinese Hamster Ovary Cell Lipid Metabolism Results in an Expanded ER and Enhanced Recombinant Biotherapeutic Protein Production | 7        |
| SESSION 3: SYSTEMS AND SYNTHETIC BIOLOGY FOR IMPROVED CELL CULTURE  |          |
| The microRNA Landscape of the Extracellular Vesicles Generated by Chinese Hamster Ovary  Cells Under Normal and Stressed Conditions             | 8        |
| GalMAX: Model-Inspired Glycoengineering for Biopharmaceutical Quality Assurance   | 9        |
| Systems and Synthetic Biology Approaches Towards Optimization of N- Glycan Sialylation  | 0        |
| Metabolic Engineering of High-Productivity CHO Host Lines for Biomanufacturing  | 1        |
| Biologics 4.0: Emergence of the CHO Biofoundry  | 2        |
| Feedback-Responsive Cell Factories for Biomanufacturing   | 3        |
| What Does a Cell Need for Efficient Protein Secretion: Deciphering, Modeling, and Augmenting the CHO Machinery                                  | 4        |
| Synthetic Cell Lines for Recombinant AAV Production   | 5        |
| Transcriptomics Guided Mechanistic Metabolic Model for Perfusion Culture Process  | 6        |
| SESSION 4: ANALYSIS AND CONTROL OF CELL CULTURE-BASED MANUFACTURING   | <u> </u> |
| Advanced Control of Glycosylation and Titer in Fed-Batch Monoclonal Antibody Production   | 7        |

Anne Robinson

| Effective Cell Culture Operations by Implementing Accurate, Non-Invasive Determination of the Critical Process Parameter pH in Roche's Drug Substance Network   | 28 |
|---|----|
| Real-Time Data-driven and Multi-scale Model-guided System for Bioproccess Digital Twin Platform   | 29 |
| Upstream Control Strategy Development for Afucosylated Species in mAb Biomanufacturing  | 30 |
| Bioreactor Scale Induced Alteration in Cell Metabolic State Can Impact Amino Acid<br>Misincorporations in Recombinant Proteins Produced in CHO Cells  | 31 |
| Machine Learning and Advanced Data Analytics Automating the Exploitation of Raman Spectroscopy: from Micro-Scale to Large-Scale Operation   | 32 |
| SESSION 5: CCE FOR CELL-BASED THERAPIES   |    |
| Adaptive T Cell Processing Through Integrated Process Analytical Technologies   | 33 |
| Process Analytical Utility of Raman Spectroscopy for Cell Therapy Manufacturing   | 34 |
| A Soft Sensor of Cell Concentration in a Perfusion Bioreactor Via a Digital Twin  | 35 |
| Rapid, Scalable, Cost-Effective Process for Generation of Stably Integrated Chimeric Antigen Receptor (CAR) Engineered T-cells by "Gene Writing": An All RNA Approach, Without Need for Use of Viral Vectors Or Nucleases  **Madhusudan V. Peshwa** | 36 |
| Advancing Manufacture of hiPSC-Derived Hepatocytes with Improved Functionality: A Nature-inspired Protocol  | 37 |
| AI-Enabled Biomanufacturing   | 38 |
| Engineered T-Cell Therapy: State of the Science Susan Abu-Absi  | 39 |
| Differential Effects on Natural Killer Cell Production by Membrane-bound Cytokine Stimulations  | 40 |
| SESSION 6: PRODUCTION OF VIRAL VECTORS AND OTHER EMERGING THERAPEUTIC MODALITIES  |    |
| Overcoming Barriers in Viral Vector Manufacturing: Small Molecule Targeting of Antiviral Defences   | 41 |

| Scalable, Serum-Free Cell Culture Platform for Improved Production of Diverse Live Virus and Viral Vector Vaccine Candidates  James Wagner   | 42    |
|--|-------|
| Advancing the Productivity, Robustness, and Scalability of AAV Production Process by Transient Transfection in Suspension Cell Culture  Jenny Shupe  | 43    |
| Development of a Second-Generation Lentiviral Vector to Reduce COGM While Meeting Both Vector and CAR T Cell CQAs  | 44    |
| A Hot New Bioprocess Strategy to Improve Small EV Production   | 45    |
| Development of a Subclonal Host Cell Line for AAV Production   | 46    |
| SESSION 7: CELL CULTURE FOR INTEGRATED AND CONTINUOUS BIOPROCE   | SSING |
| Ultra-Intensified Intermittent-perfusion Fed-batch (UIIPFB) Process Quadrupled Productivity of a Bispecific Antibody   | 47    |
| Scaleable Microscale Perfusion Systems for Yeast and Mammalian Cells to Accelerate Process  Development of Bioproducts   | 48    |
| Development of a Highly Concentrated Perfusion Medium Supplement to Decrease Media Demand Leveraging a Newly Designed 250 mL Single Use Perfusion Bioreactor   | 49    |
| Maintaining Productivity Over Extended Durations for Perfusion Processes   | 50    |
| On Digital Bioprocessing for Manufacturing Intelligence: Application of Process Analytical Technology (PAT) and Process Data Analytics (PDA) for Upstream Process Development and Intensification      | 51    |
| POSTER SESSION   |       |
| Case Study: Optimization Stage of a Bispecific DART® Molecule Identified Dissolved Carbon Dioxide (dCO <sub>2)</sub> is a Critical Upstream Process Parameter for Growth, Productivity and Scalability | 52    |
| The Impact of Expression Vector Position on Transgene Transcription Allows for Rational Expression Vector Design in a Targeted Integration System  | 53    |
| Co-Culturing Cell Lines for Efficient Manufacture of Multispecifics  | 54    |
| Analysis of Production Bottlenecks in BiTE® Molecules Producing CHO Cells  | 55    |

| From Nanoliter to Large-Scale Bioreactors: How Integrated Technologies Bring Antibody Treatments to Patients Faster   | 56 |
|---|----|
| Véronique Lecault   |    |
| Fast Track Fed-Batch Culture Development for COVID-19 Vaccine Clinical Study  | 57 |
| Polyclonal Production of Antibodies Using CHO Cell Line Mixtures  | 58 |
| Designing a Highly Productive Next Generation CHO Fed Batch Platform  | 59 |
| Rescue Protein Production with Effector Gene Determination in CHO Cells   | 60 |
| Design, Expression, and Characterization of an Asymmetric Bispecific Antibody Fused to a scFv Shuttle for Brain Uptake  | 61 |
| Designing a CHO Protein Production Platform Using Multi-Omics Technology  | 62 |
| Streamlining T Cell Engager Development with a Diverse Panel of Fully Human CD3-Binding Antibodies, Bispecific Engineering Technology, and an Integrated Discovery Engine | 63 |
| Mitigating Development Risk of Complex Modalities During Early-Stage Cell Line Development  Ren Liu   | 64 |
| Fucosylation Inhibitor Development for Producing Afucosylated Antibodies  | 65 |
| A Production-Adapted, Multi-Auxotrophic, CHO Cell Line for Reducing Monoclonal and Bispecific Antibody Cell Line Development Timelines                                    | 66 |
| High Throughput Analysis for Cell Line Development  | 67 |
| Process for Generation of High-Producing CHO Cell Lines for Biomanufacturing of Biologics Using Our CHOrcTA Platform  Simon Joubert                                       | 68 |
| Identifying Early Predictors of Instability in CHO Cell Lines Using the Berkley Lights Beacon® Optofluidic System  James Donaldson  | 69 |
| Engineering Chinese Hamster Ovary Cells for Enhanced Protein Secretion  | 70 |
| Power of Platform to Accelerate Therapies Beyond a Pandemic   | 71 |
| Engineering CHO Cell Lines for the Production of Biosimilars of Murine Cell Derived Reference Products  | 72 |

| Novel Directed Evolution Platform for Creating High-Productivity Cells for Therapeutic Protein Production, Virus Production, and Other Processes | 73 |
|--|----|
| A Novel System for Glycosylation Engineering by Natural and Artificial Micrornas   | 74 |
| Fine Tuning of Plasmid Design to Generate Tailored CHO Cell Lines for Production of Bi- and Multispecifics                                       | 75 |
| Rebuilding CHO Again and Again: Development of a Species Agnostic Modular Cell Line Development Platform for Cultivated Meat                     | 76 |
| Modulation of Sialic Acid Content for Enzyme Fusions Using Combinatorial Approach of Cell Line Engineering and Process Development               | 77 |
| High Yielding Large-Scale Transient Expression of Biotherapeutics in CHO: Beyond Preclinical Development   | 78 |
| Omics-Based Characterization of Random Transgene Integration Sites from CHO Production Cell Lines  | 79 |
| High ER Content and Upregulated UPR Pathway Render a Unique CHO Host with High Antibody Productivity and Product Quality                         | 80 |
| Engineered Transposon for Improved Cell Line Development   | 81 |
| Characterization of Extrachromosomal Circular DNA (eccDNA) Structure, Function, and Dynamics in a CHO K-1 Clone                                  | 82 |
| Identification of Transgene Integration Sites, Their Structure and Epigenetic Status with Cas9-<br>Targeted Nanopore Sequencing in CHO Cells     | 83 |
| Genome-Wide CRISPR-Cas9 Screen Identifies Hyperosmotic Stress Responsive Genes in Chinese Hamster Ovary Cells                                    | 84 |
| NextGen Sequencing (NGS) Platform and Applications in Cell Line Development  | 85 |
| Characterization of Neutralizing Human Anti-Tetanus Monoclonal Antibodies Produced by Stable Cell Lines  | 86 |
| Ana Maria Moro   |    |
| Finding the Ideal: Single-Cell Cloning and Seamless Media Transitions  | 87 |

| Automation of a Cell Culture Process with Lager Vessels   | 38  |
|---|-----|
| Enhancing Recombinant Protein and Viral Vector Production in Mammalian Cells by Targeting the YTHDF Readers of N6–methyladenosine in mRNA         | 39  |
| CRISPR Activation Screening of Dormant Genes to Improve Secretory Capacity in CHO Cells   | )() |
| Dynamic Regulation of Mitochondrial Metabolism as a Strategy to Maximize mAb Production in Industrial CHO Cell Cultures                           | )1  |
| Transposase-Mediated Transgene Integration for Rapid Generation of High-producing Stable Cell Lines   | )2  |
| Lauren Kraft  |     |
| Applying Synthetic Biology and Computational Biology to Advance Biologics Expression  Platforms   | )3  |
| Haewon Chung  |     |
| Development of a High Throughput CHO Cell Glycosylation Enzyme Mrna Expression Profiler   | )4  |
| Use of Stable CHO Pools and CHO TGE to Accelerate SARS-CoV-2 Vaccine Development  | )5  |
| Novel Cell Engineering Platform for Increasing Specific Productivity of CHO Cells for Therapeutic Antibody Production in Fed-Batch Cultures       | )6  |
| Cell Lines Development Through Targeted Integration Involving a CRISPR-Mad7-based System in CHO-DG44  | 97  |
| Dubhe Beatriz Bulte Ocaña   |     |
| Transcriptional Response to Recombinant Protein Production in Isogenic Multi-Copy CHO Cells   | 8   |
| A Microplate-Based Assay for Analyzing Purity and Mispairing of Bispecifics and Other Complex Molecules in Cell Culture Samples                   | 99  |
| Prediction of CHO Cell Line Stability Using Expression of DNA Repair Genes  | )() |
| Methylation Inhibition for Coping with Epigenetic-Based Heterogeneity of CHO Cell Subclones and Improving Recombinant MAB Production              | )1  |
| Simultaneous Genetic Engineering and Culture Media Manipulation Improve rh-EPO Productivity Through Lactate Re-metabolization on CHO Cell Culture | )2  |
| Further Accelerating Cell Line Development and CMC Timeline: The Journey from COVID to non-COVID Programs   | )3  |

| High-Throughput Clone Ranking Method for Rapid Clone Selection  | 104 |
|---|-----|
| Hybrid Cell Line Development System Utilizing Site-Specific Integration and Methotrexate-<br>Mediated Gene Amplification in Chinese Hamster Ovary Cells   | 105 |
| A Mathematical Modeling Framework for Determining the Probability of Obtaining a Clonally-<br>Derived Mammalian Cell Line   | 106 |
| Development of a High-Density CHO-C System Enables Rapid Protein Production in 10 Days  | 107 |
| Subcellular Fractionation Coupled to Shotgun Proteomics Allows the Identification of Novel Targets of the Classical Secretion Pathway Associated with Increased Productivity in Recombinant CHO Cells  Norma A. Valdez-Cruz | 108 |
| CRISPR/Cas9 as a Tool to Correct Point Mutations in a Recombinant Monoclonal Antibody Gene in the Genome of CHO Cells   | 109 |
| Assessment of Cloning Efficiency and Error Rates of Different Single-Cell Dispensing and High-resolution Imaging Technologies   | 110 |
| Investigating "Difficult-To-Express" mAb Frameworks in Transient and Site-specific Integration-based CHO Expression Systems   | 111 |
| Enabling Pandemic Speed to Clinic for SARS-CoV2 Neutralizing Antibodies   | 112 |
| Profiling Inc-RNA in CHO Cells Using NGS Technologies   | 113 |
| Beyond Exponential Phase: Metabolic Phenotypes in the Stationary Phase of CHO Cell Cultures  Jerneja Štor   | 114 |
| Slowly Co-Fluctuating Gene Expression Patterns Are Heritable and Associated with Stress Resistance and Improved Productivity in CHO Cell Line Development   | 115 |
| Blueprint from Nature: Multi-Omics Comparison of CHO and Plasma Cells Unveils Novel Cell Engineering Targets to Improve Productivity  | 116 |
| From Observational to Actionable: Rethinking Omic Studies in Biopharmaceutical Protein Production   | 117 |
| Investigation of the Role of Ubiquitination in ER Stress Mechanisms in Recombinant CHO Cells  Paula Meleady   | 118 |
| Role of TXNIP in Metabolic Shift to Lactate Consumption in CHO Cell Fed-Batch Cultures  | 119 |

| Workflow for Mining Process Relevant Knowledge from Transcriptomics   | 120 |
|---|-----|
| Model-Based Medium Optimization Methodologies in High-cell Density Perfusion Culture  | 121 |
| Learning Mechanistic Metabolic Models with Small Datasets   | 122 |
| Leveraging Single-Cell and Bulk Transcriptomics Towards Improved Insect Cell Factories for Biopharmaceuticals   | 123 |
| Integrated Platform for High-Throughput Media Optimization  | 124 |
| Amino Acid Degradation Pathway Inhibitors Trigger Apoptosis in Chinese Hamster Ovary Cells  Veronica Martinez   | 125 |
| Improving Bone Morphogenetic Protein Production in CHO Cells by Understanding Its  Maturation, Signaling, and Endocytosis  Gyun Min Lee                       | 126 |
| NEXT-FLUX (Neural-net EXtracellular Trained Flux Constraints)   | 127 |
| Targeted DNA Methylation of Endogenous Promoters and the CMV Promoter Entails Distinct and Subsequent Histone Modification Changes in CHO Cells               | 128 |
| Comprehensive Meta-Analysis of the CHO Coding Transcriptome   | 129 |
| Establishment and Application of a Multiomics Systems Biology Approach for Cell Culture  Process Development and Optimization                                 | 130 |
| Metabolic Engineering of CHO Cells Towards Cysteine Prototrophy   | 131 |
| Screening of Chemically Defined Basal and Feed Media Formulations for IgM Production  | 132 |
| Enhancing CHO Cell Productivity Through a Novel Dual Selection System Using Aspg and Gs in Glutamine Free Medium  | 133 |
| Mechanistic Insights into the Metabolization of S-Sulfocysteine by CHO Cells Using a Multiomics Approach  Melanie Nguyen                                      | 134 |
| Genome-Scale Modelling of Resource Allocation in CHO Cell Metabolism  | 135 |
| Using Next-Generation Sequencing Technology, RNA-Seq, to Understand the Chinese Hamster Ovary (CHO) Cell Transcriptome Under Industrially Relevant Conditions | 136 |

| Design of Experiments Guided Control of Waste Inhibitory By-Products in High Density CHO Cell Cultures   | 137 |
|--|-----|
| Pranay Ladiwala  | 137 |
| Intracellular Factors Influencing Protein Aggregation in CHO Cell Culture  | 138 |
| A User-Friendly Tool Using Systems Biology Models to Infer Cell Functions from Omics   | 139 |
| Multi-Omics Strategy for Cell Culture Medium Optimization in Fed-Bach CHO Cell Cultivation   | 140 |
| Advanced Cell Culture Performance by Rational Media Design Based on in Depth Process  Understanding  | 141 |
| Elucidating Dipeptide Utilization and Metabolism by CHO Cells for Improved Cell Culture Performance  | 142 |
| Precision Editing of the CHO Genome Via CRISPR-Based Prime Editing: Progress and Challenges  Nicholas Sandoval   | 143 |
| Scale-Down Model Qualification Study Identifies Parameters to Improve Full-scale Robustness  | 144 |
| Feedback Control of Intensified Fed-Batch Mammalian Cell Culture Using Inline Raman  Spectroscopy  Thaddaeus Webster   | 145 |
| Loss of Cell Viability is Tracked by Decreased Cytoplasmic Conductivity  | 146 |
| A Completely Automated High Inoculation Density Fed Batch Process that Accommodates Clonal Diversity and Routinely Doubles Space Time Yield as Compared to Low Inoculation Density Processes | 147 |
| Brandon Downey   |     |
| Development of a New Control Strategy Based on Prior Knowledge that Enables Rapid and Streamlined Process Characterization   | 148 |
| Robust Cell Culture Performance Facilitated by Comprehensive Equipment Characterization – the Importance of Hydrodynamic Stress  | 149 |
| Getting a Foot in the Door: Implementing Online Cell Growth Monitoring in Manufacturing for Both Legacy and New Processes  | 150 |
| Introducing Seahorse Analyzer to Mammalian Cell Culture Process Development  | 151 |
| Multivariate Data Analysis of GMP Cell Culture Bioprocessing in Pfizer   | 152 |

| Fully-Automated Bioreactor Process Control Eliminates Hands-on Time Through Closed-loop  Cloud Software Integration              | 153 |
|--|-----|
| Adam Carcella  |     |
| A Scalable 3D Printed Bioreactor for the Expansion of Anchorage-Dependent Stem Cells   | 154 |
| Achieving Product Quality Targets While Maintaining High Titer in CHO Cell Culture Processes                                     | 155 |
| Improving Iron Tolerance and CHO Cell Culture Performance Via Adaptation in High-Iron Chemically Defined Media                   | 156 |
| Hybrid Dynamic Model of Monoclonal Antibody Production Using CHO Cells   | 157 |
| Quantitative Assessment of Desirability of Platform Cell Culture Media   | 158 |
| Integrated Microfluidics for At-Line Culture Monitoring of Proteins and Metabolites  | 159 |
| Developing a Control Strategy for Sequence Variants  | 160 |
| Short Chain Fatty Acids Produced by CHO Cells Enhance Their Specific Productivity in Fed-Batch Cultures                          | 161 |
|  |     |
| Image-Based Machine Learning Model Development of Cell Culture Attributes in Bench Top Bioreactors                               | 162 |
| Understanding the Impact of High Gas Entrance Velocity on CHO Cell Culture Processes to Improve Process Scale Up                 | 163 |
| NAD <sup>+</sup> Supplementation Improves mAbs Productivity in CHO Cells Via a Glucose Metabolic Shift  Jong Youn Baik           | 164 |
| A Less-Traveled Path for Data in Bioprocess Development: from Dynamic Experiments to  Dynamic Process Models                     | 165 |
| Explore a Probabilistic Network Model Application for Biopharma Manufacturing Process  | 166 |
| The Power of At-Line Amino Acid Measurements for Accelerated Process and Media Development of a mAb-expressing CHO Cell Line     | 167 |
| Challenges We Just Couldn't IgG-Nore: Case Studies of Process Optimization for Next-Generation, Highly Engineered Multispecifics | 168 |

| Modeling the Effect of Gradients on Cell Culture Performance in Various Large Scale Bioreactors   | 169 |
|---|-----|
| Modeling the Effect of Bioreactor pH on Chinese Hamster Ovary (CHO) Cell Metabolism and Site-Specific N-linked Glycosylation of VRC01   | 170 |
| Targeted Modulation of Biochemical Pathways to Optimize the Balance Between Productivity and Product Quality in Biosimilars   | 171 |
| Modulation of Product Quality of Biosimilars Using Metabolic Modelling to Achieve Robust Process Control  | 172 |
| Peptide-Based Solutions to Reduce Undesired Cell Culture Media Chemistry – New Options for Stabilized Media Formulations  | 173 |
| Achieving Desirable Product Quality by Modulating Cell Culture Via Real Time Analysis   | 174 |
| Achieving Product Quality Comparability While Making Cell Culture Process Changes   | 175 |
| Development of Real-Time Monitoring System and Data-driven Digital Twin Models for Forecasting Multi-step Ahead Cell Culture Performance Seo-Young Park   | 176 |
| Upstream Process Development Approach to Selectively Reduce One Or More Unpaired Cysteines of a Monoclonal Antibody   | 177 |
| Validation of the Model-Based Cell Culture Media Design Platform "CELIA" for Biomass and Product Optimization in a Bioreactor Setting   | 178 |
| Next-Gen Glycoengineering: Combining Cellular and Metabolic Engineering to fine-tuneβ1,4-Galactosylation  | 179 |
| Lectin-Aided Flow Cytometry Reveals a Close Correlation Between Cell Surface and mAb Glycosylation- Aided Flow Cytometry Reveals a Close Correlation Between Cell Surface and mAb Glycosylation | 180 |
| CHO Stable Pool Fed-Batch Process Development of SARS-CoV-2 Spike Protein Production  | 181 |
| Synthetic Cell Lines for Recombinant AAV Production   | 182 |
| Small Scale Cell Culture Based Assay for Predicting Antibody Reduction Susceptibility   | 183 |

| Quantitation of Amino Acids in Diverse Mammalian Cell Culture Media Types with the REBEL  | 104 |
|---|-----|
| At-Line Analyzer  | 184 |
| Characterization of Cell Cycle and Apoptosis Using Flow Cytometry for Bioprocess Monitoring   | 185 |
| Achieving High Titer in a Non-Platform CHO Cell Culture Process When Converting to an Internal Medium Platform  | 186 |
| Real Time Monitoring of Commercial Manufacturing and Quality Control for Enhanced Process and Method Reliability  | 187 |
| Amino Acid Analysis to Support a Genome-Scale Nutrient Minimization Forecast Algorithm for Controlling Essential Amion Acid Levels in CHO Cell Cultures | 188 |
| Closing the Loop on Cell Culture Analyzer Variability   | 189 |
| Dynamic pH Profiles Drive Higher Cell Specific and Volumetric Productivity  | 190 |
| Accelerating Attribute-Focused Cell Culture Process Development Through the Deployment of an Automatic Assay Preparation Platform                       | 191 |
| Computer Simulations of the Shear Stress/energy Dissipation in Peristaltic Pumps  | 192 |
| Development of a High-Throughput Workflow for Upstream Process Control  | 193 |
| Controlling pCO <sub>2</sub> in High Density Perfusion Cultures   | 194 |
| At-Line Investigation of Capacitance for Assessing Biomass of Mammalian Cell Culture and Fixed Cell Calibration Standard                                | 195 |
| Investigating Cell Culture Process Parameters and Galactosylation Using Media Buffering  Experiment and Digital Twin Modeling                           | 196 |
| Cell Culture Oxygen Utilization as Orthogonal Measure of Biomass for Feed Control   | 197 |
| Transcriptional and Metabolic Response of CHO Cells to Different Carbon Dioxide Concentrations  Jorge Campano   | 198 |
| Tracking Amino Acid Metabolism in CHO Cell Cultures Using Stable Isotope Labeling Assisted  Metabolomics  Maciek Antoniewicz                            | 199 |

| Developing Methodologies to Optimise Production of Recombinant Antibodies at Specific Phases of Chinese Hamster Ovary (CHO) Cell Culture | 200 |
|--|-----|
| Ellie Hawke  |     |
| Model-Based Scale-up of CHO Cell Culture Process   | 201 |
| Understanding the Effect of Oxidative and ER Stress on CHO Cell Culture and Product Quality Through Multivariate Analysis                | 202 |
| Lifecycle Management of a Commercial Platform Monoclonal Antibody Process: the Promise of ICHQ12   | 203 |
| Cillian McCabe   |     |
| Combined Effect of Ammonia Stress and Cell Line Age on CHO Cell Derived VRC01 Monoclonal Antibody Glycosylation                          | 204 |
|  |     |
| DNA Sequence to a Million Doses of COVID-19 Therapeutic Antibody in 9 Months – Making the Seemingly Impossible, Possible                 | 205 |
| Characterization of Cellular Viability Drop During Media and Platform Development  | 206 |
| Expression of Stress Proteins During Fed Batch and Perfusion Cultures  | 207 |
| Real-Time Bioprocess and Automated Feed Control with In-line Raman Sensor  | 208 |
| Mixing and Mass Transfer in Shake Flasks and Their Relationship with Antibodies Productivity of CHO Cells                                | 209 |
| Mauricio Trujillo-Roldan   |     |
| Generation and Characterization of a Process-Specific HCP Reagent Using Stably Transfected Null Cell Pools                               | 210 |
| Sven Loebrich  |     |
| High Density Culture of Human Induced Pluripotent Stem Cells in Stirred Tank Bioreactors for Regenerative Therapies                      | 211 |
| From Product Microheterogeneity to Homogeneity Using Integrated Modeling Methodology and   |     |
| New Cell Culture Component   | 212 |
| Transient Expression of CHIKV VLP in Large Stirred Tank Bioreactors  | 213 |
| Automation of an N-1 Perfusion Process Using BioCapacitance  | 214 |
| Multifunctional Surface Modifications to Capture and Expand Flowing Endothelial Colony-<br>Forming Cells                                 | 215 |

| Design and in Vitro Validation of Smart Microcarriers for Next Generation Cell Culture  | 216 |
|---|-----|
| Proof-Of-concept of a Novel Scalable Magnetic Bead-based Cell Separation Technology   | 217 |
| Immunocompetent Human 3D Brain Cell Cultures to Advance ATMP Development  | 218 |
| Novel Vertical-Wheel Bioreactors for the Scalable, Robust and Efficient Production of Shear-Sensitive Cell Therapy Products – Human Pluripotent Stem Cells (aggregate Culture) and Mesenchymal Stromal Cells (microcarrier Culture) | 219 |
| Encapsulation of Mesenchymal Stem Cells and MCF-7 Cancer Cells in Aqueous Two-phase Systems Droplets for 3D Culture Applications  | 220 |
| Integration of Pancreatic Aggregates into BioSilk Network to Treat Diabetes   | 221 |
| Development of a Dynamic SH-SY5Y 3D Culture Model for Biological Evaluation of Alzheimer-induced Pathology  | 222 |
| Novel Cell Engineering Platform for Improving Production of AAV for Gene Therapy Applications<br>Kathy Ngo  | 223 |
| Environmental Footprint of Adherent Cell Culture Viral Vector Drug Substance Manufacturing Process  | 224 |
| Advancing Large-Scale Production of MSC-derived Extracellular Vesicles Through Cellular Preconditioning and Enhanced Process Control  | 225 |
| A Scalable and Flexible Solution for Robust T Cell Expansion  | 226 |
| Simple and Convenient Method for Adipose-Derived Mesenchymal Stem Cells Serum-free  Medium Development  Joon-Chul Lee   | 227 |
| Novel Impeller Design for Stem Cell Bioprocessing and Its Application in hMSC Stirred-Tank Bioreactor Cultures  | 228 |
| Towards the Design of a Feeder-Free System for Natural Killer Cell Expansion  | 229 |
| Ex Vivo Expansion and Differentiation of Erythroblasts: from Culture Dishes to Stirred Tank Reactors for the Production of Red Blood Cells  | 230 |
| Cell Therapy Process Development with a 2 mL Perfusion Bioreactor   | 231 |

| Utilisation of Capacitance Measurement (dielectric Spectroscopy) to Monitor, Control and Improve Viral Vector and Virus-Based Vaccine Production          | 232 |
|---|-----|
| The Role of Extracellular Vesicles in the Modulation of the Cell Density Effect   | 233 |
| Jesús Lavado García   | 200 |
| Continuous Harvesting of Retroviral Murine Leukemia Viral Vector Particles in a High Cell  Density Perfusion Cultivation                                  | 234 |
| Influenza a Virus OP7 Defective Interfering Particles: Cell Culture-Based Production and Antiviral  |     |
| Efficacy in Vivo  | 235 |
| Scaleable Transient Transfection of Intensified rAAV Production Processes   | 236 |
| Towards Large-Scale Production of Human-induced Pluripotent Stem Cell-derived Extracellular Vesicles in Stirred-tank Bioreactors                          | 237 |
| Simplifying Manufacturing and Control of Dual Vector AAV Therapies  | 238 |
| Expression of Anti-Apoptotic Genes to Enhance rAAV Production   | 239 |
| On the AAVenue to Success: Advances in Technologies for AAV Production  | 240 |
| Exploring Alternative Oncogene-Free Mammalian Hosts for Adeno-associated Virus Production   | 241 |
| Design Space Determination and Process Optimization of Product Quality Attributes in Transient rAAV Manufacturing   | 242 |
| Process Improvements for AAV Production by Transient Transfection of HEK293 Cells   | 243 |
| Hybrid Liposome-Extracellular Vesciles for Targeted Delivery of CRISPR/Cas9   | 244 |
| High Cell Density Perfusion Process for rAAV9 Production Based on Transient Transfection of HEK293 Cells  | 245 |
| Accelerating the Vero Vaccine Production Platform Through the Generation of High-Density Cell Banks and Direct Thaw into Microcarrier Bioreactor Cultures | 246 |
| The Effect of Cell Density on the Plasmid Utilization for the Production of Adeno-Associated Virus Via the Triple-transfection Method                     | 247 |

| Suspension Like Scalability of rAAV9 Production in Adherent Cells  | 248 |
|--|-----|
| Intensified Virus Production in Suspension HEK293SF Cells Using High Inoculum Fed-Batch Or Low-perfusion Rate Cultures with Continuous Harvest         | 249 |
| Scalable iPSC-Based Platform to Produce Tissue-specific Extracellular Vesicles   | 250 |
| Scale Up of Sf9/BEVS-Based AAV Production Process for GMP-manufacturing of Cardiovascular Gene Therapies   | 251 |
| Medium- and High-cell-density Production of Adeno-Associated Virus Serotype 6 and the Mitigation of Cell Density Effect Via Medium Supplementation     | 252 |
| Conditioned Medium Derived from Murine BM-MSCs Cultured as Spheroids Exhibit in Vitro Immunomodulatory Capacity  | 253 |
| Process Development and Scaleup Comparisons for Transient Production of AAV  | 254 |
| Developing rAAV Production Platform with Enhanced Productivity, Scalability and Biosafety  | 255 |
| Improved Production of Viru Like Particles of Cowpea Chlorotic Mottle Virus Using the Baculovirus Expression System                                    | 256 |
| HSC70/HSP40 Overexpression in Viral Vector-Producing Sf9 Cells Impacts AAV Productivity and Product Quality  | 257 |
| Large Scale Production and Purification of a Lentiviral Vector Reference Material  Otto-Wilhelm Merten   | 258 |
| Improving Recombinant Adeno-Associated Virus Production Through Plasmid Design and Host Cell Line Optimization  Jenny Shupe                            | 259 |
| Integrated Semi-Continuous Manufacturing of Lentiviral Vectors   | 260 |
| On Demand, In-Situ Media and Buffer Preparation in Continuous Integrated Biomanufacturing to Reduce Water Consumption and CO <sub>2</sub> Footprint    | 261 |
| Leucine and Isoleucine Derivatives as Bioavailable Alternatives for Canonical Amino Acids in Cell Culture Media to Enable Next Generation Bioprocesses | 262 |
| Implementation of N-1 Process Intensification in Bioprocess Development and Production   | 263 |

| Enabling Commercial-Scale Perfusion Manufacturing Using Single-use Bioreactors and Tangential  | 264 |
|--|-----|
| Flow Filtration  | 264 |
| A Scalable Single-Use Perfusion System: Are Single-Use Bioreactors Suitable & Scalable?  | 265 |
| Scale-Up of Cell Culture Processes Using Digital Twins   | 266 |
| Toolbox for Efficient Development of High Cell Density Perfusion Process, Integrated with Continuous DSP   | 267 |
| Nils Arnold Brechmann  |     |
| Improving AAV Manufacturing by Integrated and Continuous Processing  | 268 |
| Insect Cell-Based Production Processes Intensified Via High Cell Density Perfusion and Continuous Culture  | 269 |
| Raman Spectroscopy for On-Line Monitoring of Amino Acid Concentrations and Antibody N-Glycosylation in High Cell Density Perfusion Process       | 270 |
| Development and Application of an Advanced PAT Strategy to an Integrated Continuous Drug Substance Manufacturing Process                         | 271 |
| Development and Scale-Up of Perfusion Cell Culture Process for Higer Productivity  | 272 |
| Study of the Magnetic Properties of Glioblastoma Cancer Stem-Like Cells and Non-stem Tumor Cells Using Magnetophoresis for Label-Less Separation | 273 |
| Fully Automated on Demand Cell Culture Media Preparation for Perfusion   | 274 |
| Development of Scale-Down System for Perfusion Precesses   | 275 |
| Marching Toward Implementation of an Ultra-High Density Dynamic Perfusion Process  | 276 |
| Oxygen Transfer Rate Model for Cell-Free and Predictive D.O. Control in Intensified Bioreactor Processes   | 277 |
| Process Design of a Fully Integrated Continuous Biopharmaceutical Process Using Economic and Ecological Impact Assessment                        | 278 |
| Economic and Ecological Analysis of Plastic-Degrading Enzyme Production  | 279 |

| Use of Ambr15 as a High Throughput Model to Speed Up Perfusion Bioprocess Development   | 280 |
|---|-----|
| Scalability of CO <sub>2</sub> Stripping Efficiency from Bench (3 L) to Pilot Scale (200 L) for Supporting Intensified Bioprocesses | 281 |
| Strategies for Small-Scale Perfusion Cultures in Ambr®250 HT Bioreactor System  | 282 |
| Operational Enhancements to Improve Applicability for Challenging Cell Lines in the SanofiIntensified Perfusion Platform (IPeP)     | 283 |
| Advancements on Process Development and Transfer for Integrated Continuous Biomanufacturing  David Garcia                           | 284 |
| Author Index  |     |